OneMain Financial (OMF) Prices 8M Share Secondary Offering at $53.50/Sh

Pre-Open Stock Movers 04/29: (VER) (OSTK) (FB) Higher; (ADVM) (CTXS) (EBAY) Lower (more...)

Today's Pre-Open Stock Movers:

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.

Galera Therapeutics, Inc. (Nasdaq:... More

After-Hours Stock Movers 04/28: (GRTX) (AZPN) (CAKE) Higher; (ADVM) (CMCO) (HOLX) Lower (more...)

Today's After-Hours Movers:

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.

Galera Therapeutics, Inc. (Nasdaq:... More

OneMain Financial (OMF) Announces Proposed 8M Share Secondary Offering of Common Stock

OneMain Holdings, Inc. (NYSE: OMF) (the Company) announced today the commencement of a proposed secondary public offering of 8,000,000 shares of the Companys common stock by certain entities managed by affiliates of Apollo Global Management, Inc. and Värde Partners, Inc. (together, the selling stockholders). The 8,000,000 shares of... More

OneMain (OMF) PT Raised to $72 at Credit Suisse

Credit Suisse analyst Moshe Orenbuch raised the price target on OneMain (NYSE: OMF) to $72.00 (from $69.00) while maintaining a Outperform rating.... More

OneMain (OMF) PT Raised to $72 at Barclays

Barclays analyst Mark DeVries raised the price target on OneMain (NYSE: OMF) to $72.00 (from $69.00) while maintaining a Overweight rating.... More